BR112014003414A2 - método de produção de níveis fisiológicos e terapêuticos de óxido nítrico através de um sistema de entrega oral - Google Patents

método de produção de níveis fisiológicos e terapêuticos de óxido nítrico através de um sistema de entrega oral

Info

Publication number
BR112014003414A2
BR112014003414A2 BR112014003414A BR112014003414A BR112014003414A2 BR 112014003414 A2 BR112014003414 A2 BR 112014003414A2 BR 112014003414 A BR112014003414 A BR 112014003414A BR 112014003414 A BR112014003414 A BR 112014003414A BR 112014003414 A2 BR112014003414 A2 BR 112014003414A2
Authority
BR
Brazil
Prior art keywords
nitric oxide
delivery system
oral delivery
therapeutic levels
producing physiological
Prior art date
Application number
BR112014003414A
Other languages
English (en)
Other versions
BR112014003414B1 (pt
Inventor
G Rocca Jose
S Bryan Nathan
Original Assignee
Univ Texas
Neogenis Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715502&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014003414(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas, Neogenis Labs Inc filed Critical Univ Texas
Publication of BR112014003414A2 publication Critical patent/BR112014003414A2/pt
Publication of BR112014003414B1 publication Critical patent/BR112014003414B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/02—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with a cytochrome as acceptor (1.7.2)
    • C12Y107/02001—Nitrite reductase (NO-forming) (1.7.2.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo patente de invenção: "método de produção de níveis fisiológicos e terapêuticos de óxido nítrico através de um sistema de entrega oral". a presente invenção refere-se a uma composição e a um método para fornecer óxido nítrico e terapia de nitrito para pacientes através do qual uma quantidade terapêutica está biodisponível dentro de aproximadamente 30 minutos da administração. nas modalidades da invenção, o óxido nítrico é produzido na cavidade oral.
BR112014003414-1A 2011-08-17 2012-08-17 Composição e sistema de entrega oral para aumento de níveis fisiológicos e terapêuticos de óxido nítrico BR112014003414B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524539P 2011-08-17 2011-08-17
US61/524,539 2011-08-17
PCT/US2012/051363 WO2013026000A1 (en) 2011-08-17 2012-08-17 Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system

Publications (2)

Publication Number Publication Date
BR112014003414A2 true BR112014003414A2 (pt) 2017-08-01
BR112014003414B1 BR112014003414B1 (pt) 2021-09-21

Family

ID=47715502

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014003414-1A BR112014003414B1 (pt) 2011-08-17 2012-08-17 Composição e sistema de entrega oral para aumento de níveis fisiológicos e terapêuticos de óxido nítrico

Country Status (9)

Country Link
US (3) US9241999B2 (pt)
EP (1) EP2744343B1 (pt)
KR (2) KR20140053342A (pt)
AU (2) AU2012296358B2 (pt)
BR (1) BR112014003414B1 (pt)
CA (1) CA2844910C (pt)
HK (1) HK1198870A1 (pt)
MX (1) MX354702B (pt)
WO (1) WO2013026000A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303995B1 (en) * 2008-06-13 2012-11-06 Board Of Regents, The University Of Texas System Nitrite formulations and their use as nitric oxide prodrugs
US20190314404A1 (en) * 2009-06-15 2019-10-17 Board Of Regents Of The University Of Texas System Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
EP3868389A1 (en) * 2013-05-04 2021-08-25 Board of Regents, The University of Texas System Compositions and methods for promoting nitric oxide production through an oral delivery system
US11338005B2 (en) 2013-06-28 2022-05-24 Arjuna Natural Private Limited Medicinal composition of amaranth origin for cardiovascular treatment
KR101822518B1 (ko) 2013-06-28 2018-01-26 베니 안토니 강화된 질산염 함량을 가지는 아마란스 추출물 기원의 의약 조성물 및 그의 제조방법
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
CN104256623A (zh) * 2014-10-22 2015-01-07 何瑞红 调理三高患者健康的组合物及其制备方法和应用
US11241406B2 (en) 2015-08-28 2022-02-08 Nature's Sunshine Products, Inc. Compositions and methods for acutley raising nitric oxide levels
US10624921B2 (en) 2016-11-15 2020-04-21 Berkeley Nox Limited Dietary supplements
US10702796B2 (en) 2017-09-13 2020-07-07 Thermolife International, Llc Enriched root powder products and methods of producing thereof
WO2019099003A2 (en) * 2017-11-15 2019-05-23 Berkeley Nox Limited Novel dietary supplements
US10864207B2 (en) * 2019-01-02 2020-12-15 Celagenex Research (India) Pvt. Ltd. Method of treating endothelial dysfunction

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495177A (en) * 1983-01-17 1985-01-22 Shaklee Corporation Gel tableting agent
JPH06206825A (ja) 1992-12-11 1994-07-26 Nippon Rooshiyon Kk 白癬菌、湿疹等による皮膚病の治療剤及び 皮膚殺菌活性化剤
ES2147236T3 (es) 1993-07-06 2000-09-01 Aerocrine Ab Un sistema para ser utilizado para la determinacion de niveles no en el aire exhalado y metodos de diagnostico para los trastornos relacionados con niveles anormales de no.
GB9325445D0 (en) * 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US6709681B2 (en) 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
GB9905425D0 (en) 1999-03-09 1999-05-05 Queen Mary & Westfield College Pharmaceutical composition
US6436366B2 (en) 1999-03-19 2002-08-20 Joseph V. Boykin, Jr. Prediction of wound healing by urinary nitrate assay
GB0021317D0 (en) * 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
US7128904B2 (en) 2001-01-16 2006-10-31 The Regents Of The University Of Michigan Material containing metal ion ligand complex producing nitric oxide in contact with blood
GB0119011D0 (en) * 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
GB0125222D0 (en) 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
SE526943C2 (sv) * 2002-08-26 2005-11-22 Indevex Ab Födoämneskompositionsprodukt
US7384968B2 (en) 2004-04-01 2008-06-10 Pfizer Inc. Thiazole-amine compounds for the treatment of neurodegenerative disorders
WO2005097085A1 (en) 2004-04-08 2005-10-20 Micro Nutrient, Llc Nutrient system for individualized responsive dosing regimens
US7785619B2 (en) * 2004-04-08 2010-08-31 Micro Nutrient, Llc Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens
CA2574535A1 (en) * 2004-11-15 2006-05-26 Nitromed, Inc. Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use
CA2611140C (en) 2005-06-09 2013-11-19 University Of Manitoba Compositions and methods for enhancing nitric oxide delivery
WO2008105730A1 (en) 2007-02-26 2008-09-04 Jon Lundberg Performance enhancing composition and use thereof
AT506216B1 (de) * 2008-02-13 2009-07-15 Peter Dr Hernuss Zusammensetzung zur aufnahme über mukoses gewebe
JP2011525116A (ja) * 2008-06-24 2011-09-15 マイクロファーマ・リミテッド 一酸化窒素デバイス、ならびに創傷の治癒、皮膚障害および微生物感染症の治療の方法
US8906693B2 (en) 2009-06-03 2014-12-09 University Of Florida Research Foundation, Inc. Materials and methods for measuring nitric oxide levels in biological fluids
DK2442650T3 (en) * 2009-06-12 2015-12-07 Cynapsus Therapeutics Inc sublingual apomorphine
EP2445508B1 (en) 2009-06-22 2018-11-14 VERO Biotech LLC Nitric oxide therapies
CN107260756A (zh) 2009-10-14 2017-10-20 瑟阿瓦斯克有限公司 亚硝酸盐/酯的药物制剂以及其应用

Also Published As

Publication number Publication date
US9821006B2 (en) 2017-11-21
AU2012296358A1 (en) 2014-02-27
EP2744343B1 (en) 2021-03-10
CA2844910C (en) 2017-07-11
US10342822B2 (en) 2019-07-09
WO2013026000A1 (en) 2013-02-21
EP2744343A1 (en) 2014-06-25
BR112014003414B1 (pt) 2021-09-21
MX2014001746A (es) 2014-07-09
MX354702B (es) 2018-03-16
KR20160120785A (ko) 2016-10-18
HK1198870A1 (en) 2015-06-19
KR20140053342A (ko) 2014-05-07
EP2744343A4 (en) 2015-03-04
AU2012296358B2 (en) 2016-04-21
AU2016204931A1 (en) 2016-07-28
US20160287628A1 (en) 2016-10-06
US20180153929A1 (en) 2018-06-07
US9241999B2 (en) 2016-01-26
AU2016204931B2 (en) 2016-08-18
CA2844910A1 (en) 2013-02-21
US20130071371A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
BR112014003414A2 (pt) método de produção de níveis fisiológicos e terapêuticos de óxido nítrico através de um sistema de entrega oral
NZ707377A (en) Combination therapy methods for treating proliferative diseases
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
BR112014010803A2 (pt) método de tratamento
BR112014031806A8 (pt) método para tratamento de câncer positivo para gd2
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
MX2022013590A (es) Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
BR112014016085A8 (pt) composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
NZ604029A (en) Methods of treating bladder cancer
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
IN2015DN03219A (pt)
BR112015000136A2 (pt) fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento
UA98136C2 (ru) Применение аклидиния для лечения респираторных заболеваний
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
NZ606383A (en) Methods of treating pulmonary disorders with liposomal amikacin formulations
BR112012027092A2 (pt) métodos e composiões para reduzir ou impedir a calcificação vascular durante a terapia de diálise peritoneal
EA201590933A1 (ru) Новые перорально биодоступные соединения, модулирующие контроль дыхания, и способы их использования
BR112014030813A2 (pt) tratamento de efeitos colaterais de desordens motoras e de movimento associadas com tratamentos de doenças parkinson
CY1125361T1 (el) Φαρμακευτικο παρασκευασμα υδατανθρακων για θεραπευτικη χρηση
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
MY179794A (en) Compound composition for inhalation used for treating asthma
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/195 (2006.01), A61K 31/198 (2006.01), A61K

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2012, OBSERVADAS AS CONDICOES LEGAIS.